Cantor Fitzgerald initiated coverage of Biogen with an Overweight rating and $311 price target. Cantor sees value creation being unlocked through the gradual but significant adoption of Leqembi in Alzheimer’s, Skyclarys’ rapid ascent toward $2.6B in Friedreich’s Ataxia, as well as improved oversight and profitability associated with Biogen’s still substantial business, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- QQQ ETF Update, 12/20/2023
- Biogen: EC revokes centralized marketing authorizations for TECFIDERA generics
- Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
- CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
- Biogen reports CHMP issues positive opinion for SKYCLARYS